 NextCure Inc NASDAQ: NXTC has initiated the clinical trial of its third product candidate, NC762, a humanized B7-H4 monoclonal antibody. The Phase 1 dose-escalation portion of this Phase 12 open-label trial will evaluate the safety and tolerability of NC762 in patients with advanced or metastatic solid tumors and determine its maximum tolerated dose. 